Two global randomized phase 3 studies evaluated ritlecitinib 100 mg (n=1567; exploratory 50 mg) and 50 mg (n=607; age ≥12), ...
IL-31 receptor targeting may differentiate nemolizumab by impacting pruritus-driven neuroimmune signaling while also modulating inflammation and epidermal barrier disruption. Correlative analyses ...
Intralesional BO-112 demonstrated promising clinical and pathological responses in patients with resectable basal cell ...
Icotrokinra (Icotyde) produced skin clearance through 2 years in patients with plaque psoriasis affecting the scalp, genitals, hands, and feet, with 70% achieving clear or almost ...
Day 2 of EADV 2026 highlighted new findings involving GLP-1–associated nail changes, long-term atopic dermatitis control, emerging therapies, alopecia, and hidradenitis suppurativa. The second day of ...
Trispecific blockade of IL-4/IL-13 and upstream TSLP is intended to broaden type 2 inflammatory pathway coverage and potentially enhance durability versus single-axis inhibition. Week-16 EASI 75 rates ...
The National Eczema Association (NEA) has released the State of AD 2026 National Indicator Report, a Milliman analysis ...
Nearly 95% of assessed TikTok “glass skin” videos contained potentially misleading claims, with none citing external references and none produced by dermatologists.
New data presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress highlight the effects of ...
ILT7 is selectively expressed on plasmacytoid dendritic cells, and daxdilimab binding is intended to reduce pDCs in tissue ...
Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
EPP arises from reduced ferrochelatase activity and excess protoporphyrin made largely in the bone marrow. Accurate diagnosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results